|
Re: Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
|
3
|
Resverlogix Corp.
|
Jun 09, 2020 09:13PM
|
|
What's the deal with Zenith?
|
3
|
Zenith Epigenetics
|
Jun 21, 2023 04:54PM
|
|
And 10% up again
|
3
|
Resverlogix Corp.
|
Aug 06, 2020 09:49PM
|
|
Re: #Covid19 Interview of Nevan Krogan, PDF of article
|
3
|
Resverlogix Corp.
|
Mar 27, 2020 11:25AM
|
|
Re: Two Interesting Articles - 2 of 2: COVID-19: consider cytokine storm syndromes and immunosuppression
|
3
|
Resverlogix Corp.
|
Apr 15, 2020 09:51AM
|
|
Re: Risk vs Reward moving forward!
|
3
|
Resverlogix Corp.
|
Dec 17, 2021 04:52PM
|
|
EFGR!!!
|
3
|
Resverlogix Corp.
|
Mar 27, 2020 02:13PM
|
|
Re: Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews
|
3
|
Resverlogix Corp.
|
Sep 15, 2020 09:22AM
|
|
Re: Just get it DONE $$$ DON!!!
|
3
|
Resverlogix Corp.
|
Nov 04, 2021 01:07PM
|
|
Re: Ethics Approval?
|
2
|
Resverlogix Corp.
|
Oct 12, 2021 05:50PM
|
|
Re: Eastern Capital - Expiration of warrants
|
2
|
Resverlogix Corp.
|
Jul 23, 2020 06:31PM
|
|
Re: balancing success and failure
|
2
|
Resverlogix Corp.
|
Nov 19, 2019 07:58PM
|
|
Re: Apabetalone
|
2
|
Resverlogix Corp.
|
Feb 02, 2020 12:22PM
|
|
AGM rescheduled
|
2
|
Resverlogix Corp.
|
May 28, 2024 05:03PM
|
|
Re: in the event of breakthrough...
|
2
|
Resverlogix Corp.
|
Dec 11, 2019 12:38PM
|
|
Re: Two Interesting Articles - 2 of 2: COVID-19: consider cytokine storm syndromes and immunosuppression
|
2
|
Resverlogix Corp.
|
Apr 13, 2020 08:10PM
|
|
Re: Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
|
2
|
Resverlogix Corp.
|
Mar 03, 2021 06:25PM
|
|
Volume
|
2
|
Resverlogix Corp.
|
Mar 15, 2021 11:04AM
|
|
Re: Sedi
|
2
|
Resverlogix Corp.
|
Nov 21, 2019 03:54PM
|
|
The Hepa Link?
|
2
|
Resverlogix Corp.
|
Jan 12, 2020 10:28PM
|
